In a recent report by Piramal Pharma Solutions the company attributes this to an increased focus on targeted therapeutics in disease areas such as cancer.
The global HPAPI market, which includes ADCs (antibody-drug conjugates), is expected to reach nearly $26 billion by 2022.
To take advantage of this fast-growing market, a company must be prepared to safely handle these potent compounds. According to the company this includes having the appropriate procedures, controls and expertise in-house to guarantee the safety of not just the patients who need these drugs but also the employees making them.
If these measures are not in place in-house, a company should evaluate potential partners to ensure they possess both the controls and expertise to successfully — and safely — bring its drug to market.
Click here to download the full paper.
